Update on the Role of Antipsychotics in the Treatment of Tourette Syndrome

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2012 Mar 24

PMID 22442630

Citations 16

Authors

Daniel Huys

Katja Hardenacke

Pia Poppe

Christina Bartsch

Burak Baskin

Jens Kuhn

Affiliations

Soon will be listed here.

Abstract

Tourette syndrome (TS) is a neuropsychiatric disorder with typical onset in childhood and characterized by chronic occurrence of motor and vocal tics. The disorder can lead to serious impairments of both quality of life and psychosocial functioning, particularly for those individuals displaying complex tics. In such patients, drug treatment is recommended. The pathophysiology of TS is thought to involve a dysfunction of basal ganglia-related circuits and hyperactive dopaminergic innervations. Congruently, dopamine receptor antagonism of neuroleptics appears to be the most efficacious approach for pharmacological intervention. To assess the efficacy of the different neuroleptics available, a systematic, keyword-related search in PubMed (National Library of Medicine, Washington, DC) was undertaken. Much information on the use of antipsychotics in the treatment of TS is based on older data. Our objective was to give an update and therefore we focused on papers published in the last decade (between 2001 and 2011). Accordingly, the present review aims to summarize the current and evidence-based knowledge on the risk-benefit ratio of both first and second generation neuroleptics in TS.

Citing Articles

Safety and Efficacy of Ecopipam in Patients with Tourette Syndrome: A Systematic Review and Meta-analysis.

Panda P, Panda P, Dawman L, Mishra A, Kumar V, Sharawat I CNS Drugs. 2024; 39(2):127-142.

PMID: 39730854 DOI: 10.1007/s40263-024-01140-w.

A Novel PDE10A Inhibitor for Tourette Syndrome and Other Movement Disorders.

Marshall R, Menniti F, Tepper M Cells. 2024; 13(14.

PMID: 39056811 PMC: 11274801. DOI: 10.3390/cells13141230.

Effectiveness of lifestyle interventions for improving the physical health of children and adolescents taking antipsychotic medications: protocol for a systematic review and meta-analysis.

Hawker P, Bellamy J, McHugh C, Wong T, Williams K, Wood A BMJ Open. 2023; 13(10):e073893.

PMID: 37890972 PMC: 10619077. DOI: 10.1136/bmjopen-2023-073893.

Obsessive-Compulsive Disorder, PANDAS, and Tourette Syndrome: Immuno-inflammatory Disorders.

Marazziti D, Palermo S, Arone A, Massa L, Parra E, Simoncini M Adv Exp Med Biol. 2023; 1411:275-300.

PMID: 36949315 DOI: 10.1007/978-981-19-7376-5_13.

Target-Specific Effects of Deep Brain Stimulation for Tourette Syndrome: A Systematic Review and Meta-Analysis.

Wehmeyer L, Schuller T, Kiess J, Heiden P, Visser-Vandewalle V, Baldermann J Front Neurol. 2021; 12:769275.

PMID: 34744993 PMC: 8563609. DOI: 10.3389/fneur.2021.769275.

References

Kozian R, Friederich M . [Gilles-de-la-Tourette Syndrome as a Tardive Dyskinesia]. Psychiatr Prax. 2007; 34(5):253-4. DOI: 10.1055/s-2006-952040. View

Singer H, Gammon K, Quaskey S . Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment. Pediatr Neurosci. 1985; 12(2):71-4. DOI: 10.1159/000120222. View

de Lucas Taracena M, Montanes Rada F . [Olanzapine in Tourette's syndrome: a report of three cases]. Actas Esp Psiquiatr. 2002; 30(2):129-32. View

Borison R, Ang L, Chang S, Dysken M, Comaty J, Davis J . New pharmacological approaches in the treatment of Tourette syndrome. Adv Neurol. 1982; 35:377-82. View

Lombroso P, Scahill L, King R, Lynch K, Chappell P, Peterson B . Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry. 1995; 34(9):1147-52. DOI: 10.1097/00004583-199509000-00011. View

Fountoulakis K, Samara M, Siapera M, Iacovides A . Tardive Tourette-like syndrome: a systematic review. Int Clin Psychopharmacol. 2011; 26(5):237-42. DOI: 10.1097/YIC.0b013e32834aa924. View

Pae C . A review of the safety and tolerability of aripiprazole. Expert Opin Drug Saf. 2009; 8(3):373-86. DOI: 10.1517/14740330902835493. View

Yoon D, Gause C, Leckman J, Singer H . Frontal dopaminergic abnormality in Tourette syndrome: a postmortem analysis. J Neurol Sci. 2007; 255(1-2):50-6. DOI: 10.1016/j.jns.2007.01.069. View

Jankovic J, Kurlan R . Tourette syndrome: evolving concepts. Mov Disord. 2011; 26(6):1149-56. DOI: 10.1002/mds.23618. View

10.

Shapiro E, SHAPIRO A, Fulop G, Hubbard M, Mandeli J, Nordlie J . Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry. 1989; 46(8):722-30. DOI: 10.1001/archpsyc.1989.01810080052006. View

11.

Ho C, Chen H, Chiu N, Shen E, Lue H . Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder. J Formos Med Assoc. 2009; 108(10):788-93. DOI: 10.1016/S0929-6646(09)60406-X. View

12.

Shahid M, WALKER G, Zorn S, Wong E . Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2008; 23(1):65-73. DOI: 10.1177/0269881107082944. View

13.

Kawohl W, Schneider F, Vernaleken I, Neuner I . Chronic motor tic disorder and aripiprazole. J Neuropsychiatry Clin Neurosci. 2009; 21(2):224. DOI: 10.1176/jnp.2009.21.2.224. View

14.

Kastrup A, Schlotter W, Plewnia C, Bartels M . Treatment of tics in tourette syndrome with aripiprazole. J Clin Psychopharmacol. 2005; 25(1):94-6. DOI: 10.1097/01.jcp.0000150229.69124.66. View

15.

Hounie A, De Mathis A, Sampaio A, Mercadante M . [Aripiprazole and Tourette syndrome]. Braz J Psychiatry. 2005; 26(3):213. DOI: 10.1590/s1516-44462004000300015. View

16.

Wong D, Brasic J, Singer H, Schretlen D, Kuwabara H, Zhou Y . Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology. 2007; 33(6):1239-51. PMC: 3696501. DOI: 10.1038/sj.npp.1301528. View

17.

Scahill L, Chappell P, Kim Y, Schultz R, Katsovich L, Shepherd E . A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001; 158(7):1067-74. DOI: 10.1176/appi.ajp.158.7.1067. View

18.

Gilbert D, Batterson J, Sethuraman G, Sallee F . Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry. 2004; 43(2):206-14. DOI: 10.1097/00004583-200402000-00017. View

19.

Gulisano M, Cali P, Cavanna A, Eddy C, Rickards H, Rizzo R . Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci. 2011; 32(6):1213-7. DOI: 10.1007/s10072-011-0678-1. View

20.

TRILLET M, Moreau T, Dalery J, de Villard R, AIMARD G . [Treatment of Gilles de la Tourette's disease with amisulpride]. Presse Med. 1990; 19(4):175. View